
0:00
2:14
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Weitere Episoden von „Pharmaceutical Executive“



Verpasse keine Episode von “Pharmaceutical Executive” und abonniere ihn in der kostenlosen GetPodcast App.








